ArticleBritish journal of clinical pharmacology2026
Multifactorial attribution for vancomycin-associated acute kidney injury.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multifactorial attribution for vancomycin-associated acute kidney injury.British journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimVancomycin is a cornerstone therapy for severe gram-positive infections but is known to cause acute kidney injury (AKI). Although AKI risk is concentration dependent, its heterogeneous nature in real-world polypharmacy settings remains poorly understood. We assessed the association between vancomycin exposure and AKI while identifying heterogeneous risk patterns across patient subgroups.
methodsWe conducted a retrospective analysis of electronic health records of adults receiving vancomycin from 2019 to 2023 at a tertiary medical centre in southern Taiwan. Patients aged ≥20 years who received vancomycin for ≥3 consecutive days were included. The primary outcome was vancomycin-associated AKI. The relationship between trough concentrations and AKI risk was analysed using logistic regression. Conditional average treatment effect (CATE) analysis using the X-Learner framework estimated heterogeneous risk differences across subgroups by comorbidities and concomitant medications.
resultsAmong 1611 patients (mean age 65.8 years), 374 (23.2%) developed AKI. Each 1 mg/L increase in trough concentration increased AKI odds by 8% (odds ratio 1.08; 95% confidence interval 1.06-1.10). Patients with high troughs (>15.5 mg/L) had a 31% higher absolute risk of AKI. The CATE analysis revealed substantial heterogeneity: Co-administration of β-lactams (piperacillin and meropenem) and loop diuretics increased vancomycin-attributable AKI risk, with varying risk levels across subgroups.
conclusionThe risk of vancomycin-associated AKI varied across subgroups and was influenced by concomitant medications. Loop diuretics, piperacillin and meropenem affected the association between vancomycin exposure and AKI. These findings highlight the need for comprehensive risk assessment considering medication profiles and nephrotoxic potential, rather than vancomycin concentration alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.